The Exchange had sought clarification from Indo Us Biotech Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1.Financial results submitted in XBRL with discrepancies The response of the Company is enclosed.
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE sought clarification from Indo Us Biotech Limited regarding discrepancies found in the financial results submitted in XBRL format for the quarter ended 30 September 2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. The company has submitted its response to the exchange. No penalty, fine, or adverse action has been disclosed in this filing. The matter appears to be a procedural clarification on the technical accuracy of the XBRL filing rather than a substantive issue with the underlying numbers.
This is primarily a compliance and filing-format issue, not a business or governance crisis, so immediate impact on shareholders should be limited. Investors may want to review the company's actual financial results and its response for any underlying concerns about reporting quality.